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ABSTRACT
Drug selection of rapid acting fentanyl formulations in
the treatment of breakthrough pain in patients with
cancer is performed by the System of Objectiﬁed
Judgement Analysis method. All seven available
formulations were included in the analysis. The following
selection criteria were used: number of available
strengths, variability in the rate of absorption,
interactions, clinical efﬁcacy, side effects, ease of
administration and documentation. No direct double-
blind comparative studies between two or more
formulations were identiﬁed and the clinical
documentation of all formulations is limited. The most
distinguishing criterion was ease of use. This led to
slightly higher scores for Abstral, Instanyl and PecFent
than for the other formulations. The pros and cons of
each formulation should be discussed with the patient,
and the most suitable formulation selected for each
individual patient.
INTRODUCTION
Pain is a common symptom of cancer,1–3 which is
often feared by patients and healthcare profes-
sionals. Strong opioids, such as morphine, oxy-
codone or fentanyl are the mainstay for the
maintenance treatment of severe cancer pain.4
They are usually effective in the management of
background pain, but breakthrough pain (BTP) may
still occur during treatment with slow release
opioids.
The term BTP was ﬁrst described by Portenoy
and Hagen in 1989 as “a transitory increase in pain
to greater than moderate intensity which occurs on
a baseline pain of moderate intensity or less”.5
Thereafter, several deﬁnitions have been proposed.6
BTP may occur while slow release opioids are
being used.7 This pain may be caused by actions of
the patient such as movement or coughing but may
ﬂuctuate for no identiﬁable reason. BTP should be
distinguished from exacerbations of pain that are
dose related, such as pain occurring shortly before
the next dose of analgesia (end of dose failure).7
Treatment of BTP may require rescue doses of
strong opioids.8
BTP is highly variable,9 with a prevalence
ranging from 40% to 80%,10 but prevalence rates
of 90% have been reported11 and may result from
the disease itself, disability caused by cancer, antic-
ancer treatment or other factors. It usually has a
rapid onset —that is, a time to peak severity of
5–30 min, but with a wide range extending to
1 hour (E12). Its duration is often shortlasting and
<60 min but may last for >3 hours. BTP may be
nociceptive, neuropathic or a mixture of both.3
Cancer BTP is often severe and can greatly inter-
fere with all aspects of daily living.9 12
Immediate release morphine or oxycodone for-
mulations are extensively used in the treatment of
BTP, but their pharmacokinetic characteristics have
limitations, with a relatively slow onset of action
(up to 1 hour) and duration of action of up to
6 hours. This means that drugs with a quicker
onset and shorter duration of action are needed.13
Rapid acting, transmucosal, fentanyl formulations
have been introduced in the past few years and
these are licensed for the treatment of BTP. These
formulations are assessed and reviewed in this
article.
METHODOLOGY
The System of Objectiﬁed Judgement Analysis
(SOJA) method is a model for rational drug selec-
tion.14 The relevant selection criteria for a group of
drugs are deﬁned and judged by a panel of experts.
The more important that a selection criterion is
considered, the higher the relative weight that is
given to that criterion. The ideal properties for
each selection criterion are determined and each
drug is scored as a percentage of the relative weight
for all selection criteria. The criteria, which were
used in the present SOJA method for rapid acting
fentanyl formulations and the weighting of the
authors is presented in table 1.
A Medline search was performed in September
2013 and repeated in April 2016 and ﬁnally 30
September 2016 using search terms ‘fentanyl’ and
‘breakthrough pain’ and all relevant articles regard-
ing pharmacokinetics, efﬁcacy (especially rando-
mised controlled studies in BTP in patients with
cancer) and safety were included in the manuscript.
The present score is speciﬁc for the Netherlands,
as the Dutch formulations and approved indications
were used for calculation of the score.
The fast acting fentanyl formulations which were
available in the Netherlands, Germany and the UK
were included in the analysis. These are sum-
marised in table 2.
The sublingual orally disintegrating tablet
(Abstral) should be administered directly under the
tongue at the deepest part. The tablet falls apart
almost immediately into small particles bound to a
mucoadhesive component. After adhesion, this
component dissolves resulting in release of fen-
tanyl. The sublingual tablet should not be
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swallowed, but allowed to completely dissolve in the sublingual
cavity without chewing or sucking. Patients should be advised
not to eat or drink anything until the sublingual tablet is com-
pletely dissolved. In patients who have a dry mouth water may
be used to moisten the buccal mucosa before taking the sublin-
gual tablet.15
The sublingual tablet (Recivit) contains fentanyl in the outer
layers of the tablet. Any of the tablet remaining can be swal-
lowed after 30 min.16
Oral transmucosal fentanyl citrate (OTFC) is intended for
oromucosal administration, and therefore should be placed in
the mouth against the cheek and should be moved around the
mouth using the citrate-containing sugar matrix on an applica-
tor, with the aim of maximising the amount of mucosal expos-
ure to the product. The OTFC unit should be sucked, not
chewed, as absorption of fentanyl via the buccal mucosa is rapid
in comparison with systemic absorption via the gastrointestinal
tract. Water may be used to moisten the buccal mucosa in
patients with a dry mouth. The OTFC unit should be consumed
over a 15 min period. If signs of excessive opioid effects appear
before the Actiq unit is fully consumed it should be immediately
removed, and consideration given to reducing future dosages.17
The buccal tablet (Effentora) is an effervescent formulation,
using the OraVescent drug delivery technology. The formulation
initially lowers local pH, making fentanyl more soluble in saliva.
Next carbon dioxide is released, resulting in a higher pH
increasing the proportion of (dissolved) fentanyl that is
un-ionised, which allows absorption. Carbon dioxide also
increases the permeability of the mucosal tissue. The tablet has
to be placed within the buccal cavity above a rear molar
between the upper cheek and gum and must be kept in place
until it disintegrates (usually 14–25 min). The tablet should not
be sucked, chewed or swallowed, as this will result in lower
plasma concentrations than when taken as directed. It may be
used sublingually, but clinical studies with this application are
lacking.18
The fentanyl buccal soluble ﬁlm (Breakyl) uses the BEMA
(BioErodible MucoAdhesive) technology. The BEMA drug deliv-
ery technology consists of a small, bioerodible polymer ﬁlm for
application to the mucosal membranes (inner lining of cheek).
BEMA ﬁlms were designed to rapidly deliver a dose of drug
across the mucous membranes for time-sensitive conditions or
to facilitate administration of drugs with poor oral (pill) absorp-
tion. The patient should open the Breakyl sachet immediately
before use as indicated by the instructions printed on the sachet
and use their tongue to moisten the inside of their cheek or
rinse their mouth with water to moisten the area for placement
of the buccal ﬁlm inside the mouth so that the pink side makes
smooth contact with the inner lining of the cheek. The patient
should press and hold it in place for a minimum of 5 s until it
sticks ﬁrmly; then the white side should be visible.
The Breakyl buccal ﬁlm should stay in place on its own after
this period. Liquids may be consumed after 5 min. The Breakyl
buccal ﬁlm will usually dissolve completely within 15–30 min
after application. The patient should be instructed to avoid
manipulating the buccal ﬁlm with their tongue or ﬁnger(s) and
avoid eating food until the buccal ﬁlm has dissolved.19
The intranasal fentanyl spray (Instanyl) contains a phosphate-
buffered solution of fentanyl citrate that is administered via a
single- or multidose nasal spray device. This drug is rapidly
absorbed with an arterial Tmax of 7 min and an onset time to
achieve pain relief (PR) of about 7–10 min (E14). The duration
of action is about 60 min when delivered in single bolus dose.
Cleaning of the nasal spray tip is required after each use.20
The other nasal spray (PecFent) uses the PecSys drug delivery
system (a pectin-based drug delivery system). A low-viscosity
aqueous solution contains pectin. Each spray droplet forms a gel
after contact with the nasal mucosa.
To administer the nasal spray the nozzle is placed a short dis-
tance (about 1 cm) into the nostril and pointed slightly towards
the bridge of the nose. A spray is then administered by pressing
and releasing the ﬁnger grips on either side of the nozzle. An
audible click will be heard and the number displayed on the
counter will advance by one. Patients must be advised that they
may not feel the spray being administered, and that they should
therefore rely on the audible click and the number on the
counter advancing to conﬁrm that a spray has been delivered.
Patients should be advised not to blow their nose immediately
after administration of the drug.21
NUMBER OF AVAILABLE STRENGTHS
If many different strengths are available, this allows the patient
to optimise the effective dosage during the titration period. The
available strengths are as follows:
▸ ≥6 strengths: 100%
▸ 5 strengths: 90%
▸ 4 strengths: 80%
▸ 3 strengths: 70%
▸ 2 strengths: 60%
▸ 1 strength: 50%.
Strengths for the different formulations are shown in table 3.
A second dose of Instanyl is allowed after 10 min, which
reduces the need for many formulations. PecFent can be given
in one or in two nostrils, allowing ﬂexible dosing with only two
formulations. On the other hand, this means an extra dose for
the patient, which is why we scored this in the present way.
Table 2 Included fentanyl formulations
Formulation Trade name Description
Sublingual Abstral Sublingual fentanyl orally disintegrating
tablet
Sublingual Recivit, Ethyfyl,
Dolofent
Sublingual fentanyl tablet
Oromucosal Actiq Oral transmucosal fentanyl citrate
Buccal tablet Effentora Effervescent formulation
Buccal soluble
film
Breakyl Fentanyl buccal soluble film
Nasal spray Instanyl Phosphate-buffered solution
Nasal spray PecFent Fentanyl pectin intranasal spray
Table 1 Selection criteria and authors’ weighting
Criteria RWF
Number of strengths 60
Variability in rate of absorption 50
Interactions 50
Clinical efficacy 350
Side effects 150
Dosage frequency/ease of administration 140
Documentation 200
Total weight 1000
RWF, rating weight factor.
2 Janknegt R, et al. Eur J Hosp Pharm 2017;0:1–18. doi:10.1136/ejhpharm-2016-001127
Review
group.bmj.com on November 30, 2017 - Published by http://ejhp.bmj.com/Downloaded from 
The results reﬂect the Dutch situation; there may be minor
differences in the availability of formulations in other
countries.
VARIABILITY OF ABSORPTION
A wide variety of pharmacokinetic properties may be used to
aid selection of fentanyl formulations, but only a few have any
clinical relevance. Factors such as protein binding, volume of
distribution, route of elimination and lipophilicity have little or
no effect on the efﬁcacy and tolerability of fentanyl.
Variability in dose requirements may occur because of differ-
ences in drug exposure, and incomplete absorption or a high
variability will make dose titration more troublesome.
The variability of the area under the curve (AUC) was used
for calculation of the score and was related to the SD of the
AUC. Those products with lower SD were awarded a higher
score, using the following system:
SD 40%: score 60% (100–60%).
SD 80%: score 20% (100–80%).
Results
This criterion was given a low relative weight. A high variability
in the extent and rate of absorption may certainly contribute to
the variability in clinical response, but a very high variability is
seen in the clinical response to each individual dosage of every
formulation. Thus, the role of pharmacokinetic variability is
limited in a comparison of the drugs.
Various studies were not included in the analysis because they
used different formulations from those described above.
The absorption of the sublingual formulation (studied for
Abstral) may be slower in patients with low salivary ﬂow rates.
Moistening of the oral cavity may overcome this.22
The presence of mild mucositis had a limited effect on the
pharmacokinetics of the buccal tablet, dose 200 mg. The mean
maximum plasma concentration (Cmax) was 1.14 in patients
with mucositis and 1.21 in patients without mucositis.23
An additional study investigated the intraindividual variability
in the AUC and Cmax of the buccal tablet. A low variability was
found: the coefﬁcient of variation was 11% for the Cmax and
7% for the AUC.24 Three pharmacokinetic studies were per-
formed in Japanese volunteers25–27 and the AUC and Cmax
were consistently higher in Japanese than in Caucasian patients.
The tmax is of course a relevant aspect for the treatment of
BTP in cancer. The number of comparative studies is, however,
too small to include this as a selection criterion. Two studies
compared a buccal tablet and the transmucosal formulation,
showing a quicker absorption of the buccal tablet.28 29
One pilot study showed a high variability of absorption of
Instanyl, probably because of a poor inhalation technique.30
Data concerning the variability of the AUC (expressed as the
percentage point SD in the tmax) are summarised in table 4.
No major differences in variability were seen. The variability
of the sublingual and nasal formulations was slightly less than
that of the other formulations.
DRUG INTERACTIONS
Drug interactions usually occur in a small minority of patients,
but are relevant from a formulary point of view in order to
reduce the incidence and severity of these interactions.
This criterion is a standard aspect of the SOJA methodology,
but its relevance is low because only fentanyl formulations are
included in this analysis and hence this criterion was awarded a
score of 50/1000.
If a drug has a high incidence of interactions, this may com-
plicate treatment with this drug. The lower the incidence and
Table 4 Variability of the area under the curve (AUC)*
Formulation Trade name Range (%) Mean (%) Reference Score (%)
Sublingual Abstral 27–35
32
32 31
32
68
Sublingual Recivit 34 34 Data on file 66
Oromucosal Actiq 33
56–97
30–62
37
48 33
34
35
36
52
Buccal tablet Effentora 40–52
35
52
35
46
47–52
34
47
42
27
27
25
40 37
38
39
40
18
41
42
43
28
24
25
26
60
Buccal tablet Breakyl 20–32
33
40
33 44
36
45
67
Nasal spray Instanyl 26
40
29–45
35 46
47
48
65
Nasal spray PecFent 8–49
58
40 49
50
60
*AUC, variability (standardised to 400 mg).
Table 3 Strengths for the formulations
Formulation Trade name Strengths (mg) Score (%)
Sublingual Abstral 100
200 300
400
600
800
100
Sublingual Recivit 67
133
267
400
533
90
Oromucosal OTFC Actiq 200
400
600
800
80
Buccal tablet Effentora 100
200
400
600
800
90
Buccal soluble film Breakyl 200
400
600
800
80
Nasal spray Instanyl 50
100
200
70
Nasal spray PecFent 100
400
60
OTFC, oral transmucosal fentanyl citrate.
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severity of drug interactions with each individual drug, the
higher the score for this criterion.
Results
The simultaneous use of other central nervous system depres-
sants, including other opioids, sedatives or hypnotic agents,
general anaesthetics, phenothiazines, tranquillisers, skeletal
muscle relaxants, sedating antihistamines and alcohol may
produce additive depressant effects.15–21
Fentanyl is metabolised mainly by the cytochrome P450,
CYP3A4. Potential interactions may occur when fentanyl is
given concurrently with products that affect CYP3A4 activity.
Concomitant use with strong CYP3A4 inhibitors may result in
increased fentanyl plasma concentrations, with the risk of
serious adverse drug reactions, whereas inducers may lower fen-
tanyl concentrations.15–21 This is true for all formulations of
fentanyl with no clinically relevant differences between them.
Peak fentanyl concentrations and clinical effects were minim-
ally affected by rifampicin or grapefruit juice, but rifampicin
reduced the bioavailability of fentanyl by over 60%. No pub-
lished data are available on the effects of other inducers of
CYP3A4 on the pharmacokinetics of transmucosal fentanyl.
The summary of product characteristics of the nasal spray
(Instanyl) mentions an interaction with oxymetazoline. The
Cmax was reduced by about 50%, whereas the time to reach
the peak level was doubled. The combination should be
avoided.20
All formulations are awarded 80%.
CLINICAL EFFICACY
Clinical efﬁcacy is by deﬁnition a very important selection cri-
terion for each group of drugs. The relative efﬁcacy of the fen-
tanyl formulations was determined using double-blind,
randomised comparative studies between these drugs in the ﬁrst
instance.
If these studies were not available, results from randomised
placebo-controlled studies or (double-blind or open-label)
studies with other rescue opioids were also taken into
consideration.
As the last step non-comparative studies were considered.
Studies with fewer than 20 patients in each treatment arm51–56
were not taken into consideration. Only studies with patients
with cancer pain were included in our analysis and those with
patients with non-cancer pain or with a mixed population were
excluded.
Various endpoints are used to determine clinical efﬁcacy.
▸ Pain intensity is usually determined on an 11-point scale in
which 0 means no pain at all and 10 means pain as bad as
one can imagine.
▸ Pain intensity difference (PID) between placebo and active
medication is calculated by subtracting the placebo PI from
the PI with the active compound at various time intervals,
usually baseline, 15, 30, 45 and 60 min.
▸ The sum of the PIDs (SPID) may be calculated over time as
an alternative endpoint. There is a tendency for greater statis-
tical differences using these outcomes than using the
responder rate.57
▸ Another endpoint can be clinically meaningful PI reduction.
A PI reduction of >30% or >50% is the most common
endpoint.
▸ Finally, PR or total PR over time (TOTPAR) are used as
endpoints.
We suggest referring to other publications for a more
in-depth assessment of the rationale for using each of the
endpoints.57 58
Results
Double-blind randomised comparative studies between two or
more fentanyl formulations.
Unfortunately, no studies comparing different rapid action
formulations were identiﬁed. Such studies are not easy to
perform, because cooperation of at least two companies is
necessary in order to allow a double-blind, double-dummy
(crossover) design. It is therefore unlikely that these studies will
be performed in the near future. This makes it complicated to
draw conclusions about the relative efﬁcacy (and tolerability) of
different fentanyl formulations. In the absence of such studies,
authors have tried to compare these drugs indirectly.
Open-label randomised comparative studies between two or
more fentanyl formulations.
OTFC versus nasal spray
One study compared OTFC and the nasal spray in patients with
breakthrough cancer pain.59 A total of 139 patients were rando-
mised and titrated to an effective dose (at least three of four
BTP periods had to be treated effectively) of one of the formu-
lations for six BTP periods, followed by the same procedure for
the other formulation. The primary outcome was patient-
recorded time to onset of meaningful PR. Secondary outcomes
were PID at 10 and 30 min, SPID at 15 and 60 min, ease of
administration, treatment preference and relationship between
background opioid dose and effective fentanyl dose. The study
details are summarised in tables 5–8.
A total of 86 patients completed the study. The endpoint of
the study (meaningful PR) was different from the endpoints
used in placebo-controlled studies (see below). The median time
to onset of meaningful PR was 16 min for OTFC versus 11 min
for the nasal spray. A quicker onset of PR with the nasal spray
was found in 66% of patients (p<0.001). The nasal spray also
had signiﬁcantly (p<0.001) stronger effects on PIDs at 10 (2.27
vs 1.08) and 30 min (4.15 vs 3.39). The PID differences at 5,
15, 20 and 60 min were also signiﬁcantly greater for the nasal
formulation.
The SPIDs from 0 to 15 (1.66 vs 0.85) and from 0 to 60 min
(3.52 vs 2.83) were greater for the nasal formulation than for
the OTFC formulation.59 The reasons for withdrawal (adverse
events, inadequate analgesia during the titration period, with-
drawal of consent) were comparable for both formulations.
It should be considered that (according to the respective sum-
maries of product characteristics) a second dose of the nasal for-
mulation was allowed after 10 min, whereas this was 30 min for
the OTFC formulation. This might have had an effect on the
outcomes of the study.
The study was critically discussed in the European Medicines
Agency Assessment Report for Instanyl, with a mention of
possible misconduct at one of the leading study sites: http://
www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Public_assessment_report/human/000959/WC500033144.pdf )
(accessed 18 Sep 2013).
Fentanyl pectin nasal spray versus nasal spray
One study compared the fentanyl pectin nasal spray (FPNS)
and the nasal spray in patients with breakthrough cancer pain
in a crossover design in which one to four episodes of BTP
were treated.60 A total of 97 episodes were treated with the
FPNS and 91 with the nasal spray. Contrary to most other
4 Janknegt R, et al. Eur J Hosp Pharm 2017;0:1–18. doi:10.1136/ejhpharm-2016-001127
Review
group.bmj.com on November 30, 2017 - Published by http://ejhp.bmj.com/Downloaded from 
Table 5 Baseline characteristics of randomised controlled studies
Formulations Design N Episodes Gender (% female) Age (years) Race Cancer type Pain type Opioid use Reference
OTFC
nasal spray
Open, co 86 2×6 per patient 43 55 Cau: 100% No data No data No data 59
FPNSnasal spray Open, co 62 97 pectin
91 nasal
46 63 No data (Italy) Lung: 21%
Urogenital: 17%
GI: 15%
No data Mor: 192 mg 60
SLF
Placebo
DB, co 66 10 per patient (7 SLF, 3 placebo) 54 62 White: 84%
Black: 5%
Asian: 2%
No data No data Mor: 60–1000 mg
TDF: 50–300 mg/hour
61
SLF
Placebo
DB, co 37 9 per patient (6 SLF, 3 placebo) 41 66 Asian: 100% Lung: 26%
Breast: 7%
Gastric: 7%
No data Mor: 345 mg
Oxycodone: 29 mg
TDF: 48 mg/hour
62
SLF
IRMS oral
SB 40 30 days 43 65 Spain Prostate: 25%
Lung: 15%
Breast: 15%
No data Mor: 60–1000 mg
TDF: 50–300 mg/hour
63
SLF-E
Placebo
DB, co 78 9 per patient (6 OTFC, 3 placebo) 44 65 Czechia Urogenital: 34%
Digestive: 27%
Head/neck: 15%
No data Fentanyl: 74% (no dose) 64
OTFC
IRMS oral
DB, DD, co 93 2×5 per patient 47 55 White: 92%
Black: 7%
Hisp: 1%
Breast: 16%
Lung: 17%
Colon: 15%
Prostate: 8%
Noc: 80%
Neu: 19%
Mor: 60–1000 mg (n=61)
TDF: 50–300 mg/hour (n=28)
65
OTFC
Morphine IV
Open, co 25 53 52 59 Italy Som: 36%
S/V: 12%
S/N: 12%
Vis: 8%
V/N: 8%
Neu: 16%
Mor: 120 mg 66
OTFC
Placebo
DB, co 92 10 per patient (7 OTFC, 3 placebo)
804 in total
55 54 White: 93%
Black: 5%
Asian: 1%
Breast: 23%
Lung: 18%
Colon: 13%
Uterine: 8%
Haematol: 13%
Som: 52%
Vis: 32%
Neu: 14%
Mor: 30–600 (n=63)
TDF: 50–225 mg/hour (n=21)
67
Buccal
Placebo
DB, co 77 10 per patient (7 buccal, 3 placebo)
493 in total
45 58 White: 88%
Black: 1%
Other: 10%
No data Noc: 47%
Neu: 21%
Mixed: 32%
Mor: 213 mg (equivalent) 68
Buccal
Placebo
DB, co 87 10 per patient (7 buccal, 3 placebo)
716 in total
62 54 White: 79%
Black: 8%
Other: 13%
No data Noc: 41%
Neu: 17%
Mixed: 42%
Mor: 279 mg (equivalent) 69
Buccal
Placebo
DB, co 73 9 per patient (buccal, 3 placebo) 36 61 Japanese No data Noc: 60%
Neu: 6%
Mixed: 35%
Mor: 112 mg (equivalent) 70
Buccal film
Placebo
DB, co 82 9 per patient (6 buccal film, 3 placebo)
571 in total
55 White: 90%
Black: 8%
Other: 3%
Breast: 23%
Lung: 17%
Colon: 11%
Gastric: 7%
Pancreatic: 6%
Neu: 32% 71
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studies no details were presented for the fraction of patients
using speciﬁc dosages (table 5). The study details are sum-
marised in tables 5–8. PID scores were determined at 5, 10 and
20 min. The PID scores of the FPNS and the nasal spray,
respectively, were 1.2 and 1.0 at 5 min, 2.4 and 2.2 at 10 min
and 3.8 and 3.4 at 20 min, compared with baseline. The scores
at 5 and 20 min were signiﬁcantly better for the FPNS. The
SPID scores at 20 min (7.5 and 6.7) were not signiﬁcantly dif-
ferent. The FPNS also performed better than the nasal spray at
some time points with respect to the proportion of patients
showing >33% reduction in pain intensity (at 5 min only) and
>50% reduction (at 20 min only).60
Comparative studies with other active medicines
Orally disintegrating sublingual tablet
One prospective, longitudinal study compared the orally disinte-
grating sublingual tablet with oral immediate release mor-
phine.63 Details of the study are presented in tables 5–8.
Patients with breakthrough cancer pain were randomised to
start with either the sublingual tablet or with morphine for
30 days and were then titrated to an effective dose of both
drugs. The primary endpoints were the pain intensity, frequency
of BTP requests and time to onset of relief. Primary endpoints
were assessed at days 3 (during titration), 7, 15 and 30. It was
not stated when pain intensity was determined related to the
dosage of the medicines. The sublingual tablet was better
(p<0.001) than oral morphine at all endpoints. At days 7, 15
and 30 statistical signiﬁcance was reached as early as 5 min and
showed signiﬁcantly faster time to onset of relief for the sublin-
gual tablet over the oral morphine at all stages (p<0.001).63
OTFC formulation
One double-blind, double dummy, crossover study compared
OTFC with morphine sulfate immediate release oral formula-
tions.64 Details of the study are presented in tables 5–8. Patients
with BTP were titrated to an effective dose of both drugs and
were then randomised to start with either OTFC or with mor-
phine for ﬁve doses each. The primary endpoint was the PID
score at 15 min. There was no relationship between the OTFC
and morphine doses after the titration phase. There were also
no relationships between the breakthrough dosages of rescue
medication and the dosages of background analgesia.
At 15 min OTFC produced a >33% change in PID score for
42% of treated episodes, compared with 32% of treated epi-
sodes with oral morphine (p<0.001). OTFC performed better
than morphine in its effect on PID (p<0.008), PI (p≤0.033)
and PR scores (p≤0.009) at all time intervals. The percentage of
BTP episodes for which patients needed additional medication
was similar for both formulations (2% and 1% for OTFC and
morphine, respectively).64
Another, small-scale study compared OTFC with intravenous
morphine. Details of the study are presented in tables 5–8. PID
at 15 and 30 min decreased more than 50% in 38% and 75%,
respectively, of patients treated with OTFC and in 55% and
75% with morphine IV. This difference was signiﬁcant at 15 min
(p=0.013). No signiﬁcant difference was seen at 30 min. The
effect on PID was also signiﬁcantly better at 15 min for
morphine.66
FPNS
One double-blind, double dummy, crossover study compared
FPNS with immediate release morphine sulfate (IRMS).73 The
study details are summarised in tables 5–8. The PI scores at
baseline were signiﬁcantly higher for FPNS (7.76) than for
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IRMS (7.65), p<0.05. The primary endpoint was PID at
15 min: 3.0 versus 2.7, respectively, p<0.05). The PID
remained statistically signiﬁcant at all later time points. No sig-
niﬁcant difference in the effect on PID was seen after 5 and
10 min. The mean differences in TOTPAR were signiﬁcantly
more favourable for the FPNS from 15 min onwards. More
patients achieved a PR score of 4 with FPNS (18%) than with
IRMS at 45 and 60 min, but the difference at 30 min was not
statistically signiﬁcant.73
An analysis of the above study demonstrated TOTPAR >33%
was statistically signiﬁcant better for FPNS than IRMS
(p≤0.01). It also showed statistical signiﬁcant differences in the
percentage of episodes showing clinically meaningful PR (PID
scores at 10 min p<0.05) in favour of FPNS versus IRMS. The
difference between the two products in efﬁcacy outcome mea-
sures narrows after 30 min, suggesting that the effect of IRMS
and FPNS are similar after this time. Patient acceptability scores
were signiﬁcantly better for FPNS than for IRMS at 30 and
60 min.76
An open-label comparative study also showed better efﬁcacy
of FPNS than immediate release oral morphine.74
No comparative studies with other active medicines are avail-
able for sublingual tablet, buccal soluble ﬁlm, buccal tablet and
nasal spray.
Double-blind, placebo-controlled studies
Orally disintegrating sublingual tablet
Two studies have been performed with the sublingual formula-
tion—one a phase II study and one a phase III study. The study
details are summarised in tables 5–8. Unfortunately, not all
studies provided information about the proportion of patients
requiring rescue medication.
One phase II study compared a single dose of 100, 200 and
400 mg sublingual fentanyl with placebo in a randomised, cross-
over fashion in opioid-tolerant patients with cancer. The
primary endpoint was PID from baseline, using a 100 mm
Visual Analogue Scale. Pain intensity was recorded at baseline,
5, 10, 15, 20 and 30 min. Secondary endpoints were global
assessment of treatment and the need for rescue medication. A
total of 38 patients were randomised. Of these, 27 received the
study medication and 23 completed the study. There was a sig-
niﬁcant overall improvement in the PID over the whole period
Table 6 Dose fentanyl formulations in randomised controlled studies
Formulations
Dose
fentanyl Comparator dose Reference
50 100 200 400 600 800 1200 1600
OTFC
Nasal spray
−
23
−
32
34
40
30
−
11
−
5
−
5
−
5
−
NA 59
FPNSNasal spray Pectin: 328 mg
Nasal: 165 mg
60
SLF
Placebo
4 6 7
16 (300 mg)
8 21 61
SLF
Placebo
26% 21% 10%
26%
(300 mg)
5% 2% 62
SLF
IRMS oral
Mean dose
235 mg
Mor: 38 mg 63
SLF-E
Placebo
36%
(133 mg))
31% (267 mg) 14% 13%
(567 mg)
6% 64
OTFC
IRMS oral
10% 19% 25% 15% 17% 15% 15 mg: 27%
30 mg: 46%
45 mg: 17%
60 mg: 10%
65
OTFC
Mor IV
24% 12% 20% 4% 32% 8% Fixed ratio: 200/4,
etc
66
OTFC
Placebo
No data No data No data No data No data No
data
No data No
data
NA 67
Buccal
Placebo
12 11 20 10 24 NA 68
Buccal
Placebo
8% 12% 18% 28% 34% NA 69
Buccal
Placebo
7% 14% 19% 17% 11% 6% 27% dose not
known
NA 70
Buccal film
Placebo
5% 19% 28% 24% 25% NA 71
Nasal spray
Placebo
18 48 45 NA 72
FPNS
IRMS oral
16 18 30 15 Mor: 29 mg 73
FPNS
IRMS oral
Pectin: 182 mg
Mor: 17 mg
74
FPNS
Placebo
11% 10% 33% 47% 75
FPNS, fentanyl pectin nasal spray; IRMS, immediate release morphine sulfate; IV, intravenous; Mor, morphine; NA, not applicable; Nasal, fentanyl nasal spray; OTFC oral transmucosal
fentanyl citrate; SLF, sublingual fentanyl (Abstral) ; SLF-E, sublingual fentanyl ethypharm (Recivit).
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compared with placebo (8.6 mm, p<0.0001). A signiﬁcant dif-
ference was seen after 15 min. No signiﬁcant difference was
observed between the 100 and 200 mg doses compared with
placebo. The global assessment of treatment was rated as excel-
lent in nine patients using the 400 mg dose versus 3 with
placebo (p=0.0146) and fewer patients needed rescue medica-
tion: 5 versus 15, p=0.001.77
A phase III study involving 136 patients compared the sublin-
gual formulation to placebo. Patients were titrated in an open-
label setting, followed by a double-blind, efﬁcacy phase, lasting
2 weeks, in which the titrated dose (seven episodes) was com-
pared with placebo (three episodes). Sublingual fentanyl was
associated with a signiﬁcantly stronger effect on SPID 0–30:
49.5 vs 36.6, p=0.0004) compared with placebo. This was also
the case for SPID 0–60: 143 vs 105, p=0.0002). PID was sig-
niﬁcantly lowered at all time points from 10 to 60 min,
p=0.0055, in the sublingual fentanyl group. A greater reduction
of PR was seen from 10 to 60 min, (p=0.049) with fentanyl
than with placebo. Rescue medication was needed in 11% of
fentanyl users, compared with 27% with placebo (no statistics
were provided), and global evaluation scores were better for fen-
tanyl: 3.1 versus 3.6, p=0.0006.61
One Japanese small-scale study also compared the sublingual
formulation with placebo. Patients were titrated during 3 weeks
in an open-label setting, followed by a double-blind, efﬁcacy
phase, lasting up to 3 weeks, in which the titrated dose (six epi-
sodes) was compared with placebo (three episodes). This study
used a Visual Analogue Scale of 100 mm for estimation of PID.
Sublingual fentanyl was associated with a statistically signiﬁcant
effect on PID at 30 and 60 min, whereas no signiﬁcant effect
was observed at 15 min. Global assessment of PR was scored on
a scale ranging from 4 (no relief at all) to 0 (complete relief ).
PR at 30 and 60 min was signiﬁcantly better for the sublingual
formulation (p<0.001) than with placebo (30 min: 2.0 vs 1.5,
and 60 min: 1.4 vs 0.9).62
Sublingual tablet (Recivit)
One phase III study compared the sublingual formulation with
placebo.64 Patients were titrated in an open-label setting, fol-
lowed by a double-blind, crossover efﬁcacy phase, in which the
titrated dose (six episodes) was compared with placebo (three
episodes). Sublingual fentanyl was associated with a statistically
signiﬁcant beneﬁcial effect on SPID at 30 min compared with
placebo (75 vs 53, p<0.0001). This was also the case for SPID,
Table 7 Patients in randomised controlled studies
Formulations
Titration
duration
(median)
N
Initial
Withdrawal
titration
phase Randomised
Withdrawal
study
phase
Evaluable
efficacy Mean dose Reference
OTFC
Nasal spray
▸ 8 weeks
▸ 5 weeks
196 57 139 53 86 No data 59
FPNS
Nasal spray
▸ 8 weeks
▸ 5 weeks
62 62 12 50 Pectin:
328 mg
Nasal:
165 mg
60
SLF
Placebo
2 weeks 131 53 66 6 60 600 mg 61
SLF
Placebo
3 weeks 42 5 37 5 32 No data 62
SLF
IRMS oral
7 days 40 0 40 0 40 235 mg 63
SLF-E
Placebo
2 weeks 91 13 78 5 73 64
OTFC
IRMS oral
5 days 134 41 93 9 75 811 mg
31 mg
65
OTFC
Mor IV
None 40 NA 40 15 25 No data 66
OTFC
Placebo
2 weeks 130 37 92 20 72 No data 67
Buccal
Placebo
No data 123 46 77 9 77 No data 68
Buccal
Placebo
7 days 125 38 87 12 75 69
Buccal
Placebo
21 days 103 26 73 2 73 70
Buccal film
Placebo
7 days 151 69 82 2 80 71
Nasal spray
Placebo
No data 120 7 113 3 110 72
FPNS
IRMS oral
14 days 110 26 84 5 79 73
FPNS
IRMS oral
No data 53 53 8 45 Pectin:
182 mg
Mor: 17 mg
74
FPNS
Placebo
114 31 83 7 73 75
FPNS, fentanyl pectin nasal spray; IRMS, immediate release morphine sulfate; iv, intravenous; Mor, morphine; NA, not applicable; Nasal, fentanyl nasal spray; OTFC oral transmucosal
fentanyl citrate; SLF, sublingual fentanyl (Abstral); SLF-E, sublingual fentanyl ethypharm (Recivit).
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Table 8 Efficacy endpoints in randomised controlled studies
Formulations Primary PID PID PI PR GMP/GP Reference
15 30 45 60 15
>33%
decrease
30 min
OTFC
Nasal spray
Time to pain relief 1.7 3.4
4.2
p<0.001
4.6
4.4
p<0.01
22%
54%
p<0.001
59
FPNS
Nasal spray
>33% PID 60
SLF
Placebo
SPID 30 min 2.2
1.4
1.8
1.2
p=0.0002
3.1 (PGEM score)
3.6
61
SLF
Placebo
PID 30 min 22
21
NS
VAS mm
41
34
p=0.002
VAS mm
56
45
p<0.001
VAS mm
62
SLF
IRMS oral
PI 3 days: 6.0 (SLF) vs 6.9 (M)
30 days: 3.0 (SLF) vs 4.4 (M)
p<0.001
63
SLF-E
Placebo
SPID 30 min 2.3
1.6
p<0.0001
64
OTFC
IRMS oral
PID 15 min 1.8
1.4
p<0.01
2.8
2.3
p<0.01
3.4
2.9
p<0.01
3.9
3.3
p<0.01
42%
32%
p<0.001
O<M
p<0.05
(no data)
1.8
1.5
p<0.01
2.5
2.1
p<0.001
65
OTFC
Mor IV
2.8
3.6
p=0.013
4.5
5.2
NS
57%
74%
−41%
−52%
p=0.026
66
OTFC
Placebo
SPID 1.45
0.98
p<0.0001
1.85
1.19
p<0.0001
2.15
1.64
p<0.0001
2.28
1.67
p<0.0001
1.85
1.19
1.98 (30 min)
1.19
p<0.0001
67
Buccal
Placebo
SPID 30 min 0.8
0.5
p<0.0003
2.2
1.3
p<0.0001
3.3
1.8
p<0.0001
3.8
2.1
p<0.0001
48%
29%
p<0.0001
1.3
0.8
p<0.0001
1.4 (30 min)
0.9
p<0.0001
68
Buccal
Placebo
SPID 60 min 1.4
0.8
p<0.0001
2.3
1.2
p<0.0001
2.8
1.4
p<0.0001
3.2
1.5
p<0.0001
51%
26%
p<0.0001
1.7
1.1
p<0.0001
2.1 (60 min)
1.2
p<0.0001
69
Buccal
Placebo
PID 30 min 1.2
1.0
NS
2.3
1.8
p<0.05
3.3
2.4
p<0.05
60%
42%
p<0.05 (60 min)
2.0
1.5
70
Buccal film
Placebo
SPID 30 min 1.4
1.2
NS
2.3
1.8
p<0.05
2.8
2.2
p<0.01
3.2
2.3
p<0.001
26%
21%
NS
71
Nasal spray
Placebo
PID 10 min 2.5
1.3
10 min
p<0.001
4.2
2.1
40 min
p<0.001
4.3
2.3
p<0.001
80%
45%
p<0.001
1.9
1.0
p<0.001
72
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PID, PI and PR scores from 6 to 60 min. At 15 min, 58% of
sublingual fentanyl episodes had a pain score reduction of at
least 33%, compared with 38% in the placebo group. At 30 min
these values were 72% and 51%, respectively, p<0.0001). Pain
reduction of at least 50% was observed with sublingual fentanyl
in 27% at 15 min and 53% at 30 min, and 19% and 36% for
placebo, respectively (p values 0.02 and 0.0004). Additional
rescue medication for BTP was needed in 18% of episodes
treated with sublingual fentanyl compared with 38% of episodes
treated with placebo (p<0.0001).64
OTFC formulation
One study compared OTFC with placebo.67 The study details
are summarised in tables 5–8. Intention-to-treat analysis showed
that OTFC had signiﬁcantly better effects on pain intensity and
PR than placebo at all time intervals assessed (15, 30, 45 and
60 min). The need for additional rescue medication was signiﬁ-
cantly lower in the OTFC group; 15% vs 34%, p<0.0001. The
majority of patients (80%) preferred OTFC rather than
placebo.67
Buccal tablet
Three studies compared the buccal tablet with placebo.68–70 The
study details are summarised in tables 5–8.
One study showed signiﬁcantly better effects of the buccal
tablet than placebo on SPID and TOTPAR scores at 15, 30, 45
and 60 min (p<0.0001 for almost all time points). The SPID at
30 min (the primary endpoint) was 3.0 for the buccal tablet
versus 1.8 for placebo (p<0.0001). A 50% reduction in pain
score was seen in 24% of episodes with the buccal tablet and in
16% with placebo (p=0.0023). Supplemental medication was
needed in 23% with the buccal tablet versus 50% with placebo.
This study showed no correlation between an effective dose of
fentanyl and background opioid analgesic dose.68
The second study provided information on the effects of the
buccal tablet on pain of different origins. No clear differences
were seen between the SPID for patients with pain of nocicep-
tive, neuropathic or mixed origin. TOTPAR was signiﬁcantly
better in the episodes treated with active medication.
At 30 min, a pain intensity reduction of at least 50% was
obtained in 38% for the buccal tablet versus 15% in the
placebo episodes.69
The third study was performed in Japanese subjects. PID was
signiﬁcantly better for the buccal fentanyl product than for
placebo from 30 min onwards, but no signiﬁcant difference was
noted at earlier assessments at 15 min.70
Buccal ﬁlm
One study compared buccal ﬁlm with placebo.71 The study
details are summarised in tables 5–8. The primary endpoint was
SPID at 30 min. The buccal ﬁlm scored signiﬁcantly better than
placebo for the primary end point (p<0.004). Statistical signiﬁ-
cance was seen with the SPID for the buccal ﬁlm rather than the
placebo at 15, 45 and 60 min also (p values range <0.001–
<0.05). The PID values for buccal ﬁlm were greater than for
placebo with statistical signiﬁcance seen from 30 min onwards
(p<0.05 at 30 min, p<0.01 at 45 min and p<0.001 at 60 min).
The percentage of patients with >50% decrease in PI was sig-
niﬁcantly lower at 30, 45 and 60 min, but not at 15 min. No
information was provided about the use of rescue medication,
although overall satisfaction scores showed signiﬁcant preference
for the buccal ﬁlm than for placebo.71
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Nasal spray
One study compared the nasal spray with placebo.72 The study
details are summarised in tables 5–8. The primary endpoint was
PID at 10 min. A lower PID at 10 min was found for the 50 mg
dose (PID 2.0) than for the 100 mg (PID 2.7) and 200 mg (PID
2.6) doses. By comparison, placebo resulted in a PID of 1.3 at
10 min (p<0.001). The difference between the 50 mg and the
higher dosages was maintained at 60 min. The same effect was
seen for the SPID from 0 to 60 min. A PI reduction of >33% at
10 min was observed in 58% of those treated with the nasal
spray compared with 28% treated with the placebo. Rescue
medication was used in 14% of episodes treated with the nasal
spray versus 45% for placebo.72 A further study identiﬁed was
excluded because fewer than 20 patients were included in each
treatment arm.78
FPNS
One study compared fentanyl FPNS with placebo.75 The study
details are summarised in tables 5–8. The primary endpoint was
SPID at 30 min, which was signiﬁcantly in favour of the FPNS
(SPID scores at 30 min were 6.6 for FPNS and 4.5 for placebo,
respectively, p<0.0001). At 10 and 15 min, a signiﬁcantly
greater proportion of patients had shown a reduction in PI
scores of at least one point with the FPNS versus the placebo
(p<0.01). A greater number of placebo-treated episodes needed
additional rescue medication compared with FPNS treated epi-
sodes.75 Patient acceptability was also better for the nasal
spray.79
Non-comparative studies
Non-comparative studies or studies comparing different dosage
regimens of the same formulation are not included in this ana-
lysis, but were taken into consideration for the judgement of
safety, when applicable.80–92
The number of comparative studies is disappointingly small,
which makes it difﬁcult to judge the relative efﬁcacy of different
fentanyl formulations. Only one open-label randomised study
has been performed: between OTFC and the nasal spray. In that
study, sponsored by the manufacturer of the nasal spray, the
latter drug was more effective than the OTFC formulation.59 A
second comparative study is needed before a differentiation in
score can be made, however. The other formulations have only
been compared with placebo and not with each other. The
results of these studies cannot be compared directly, because of
differences in applied endpoints, patient population, dosages,
fraction of patients with neuropathic pain, response to placebo
and baseline BTP intensity (see tables). The criteria for deter-
mining successful dosing during the titration phase were differ-
ent in most studies, which might affect outcomes. The time
before study participants were allowed additional breakthrough
rescue medication ranged from 10 to 60 min, which might also
inﬂuence efﬁcacy.
Only one study was performed with the buccal ﬁlm.71 The
effects at 15 and 30 min seem to be less favourable than with
the other formulations. This may correlate with a relatively slow
absorption, with a tmax of up to 2 hours. The buccal ﬁlm is
awarded 60% for efﬁcacy. All other formulations are awarded
70%.
In the absence of comparative studies, Zeppetella conducted a
network meta-analysis, comparing the different fentanyl formu-
lations. However, owing to the design of this study, it is difﬁcult
to draw any ﬁrm conclusions.83
SIDE EFFECTS
The incidence and severity of side effects is an important selec-
tion criterion. The lower the incidence and severity of observed
adverse drug-related events, the higher the score.
Results
The comparative studies provide limited information on the tol-
erability and safety of the formulations. In many cases no dis-
tinction between the adverse events in both treatment arms is
provided and it is not always possible to assess whether adverse
events were due to the study medication or to the disease or the
maintenance opioids.
All studies were too small scale and of too short a duration to
make ﬁrm statements about the safety of the formulations.
OTFC versus nasal spray
One open-label study compared the OTFC tablet and the nasal
spray in patients with breakthrough cancer pain.59 The total
incidence of adverse events was 35% for OTFC and 46% for
the nasal spray; no statistics were provided to indicate whether
this was a signiﬁcant difference. Adverse events possibly or def-
initely related to treatment were seen in 19% of patients with
OTFC and in 12% with the nasal spray. Serious adverse events
were seen in 14% of patients with the nasal spray versus 8%
with the OTFC. None of these serious adverse events was con-
sidered to be treatment related. The most common adverse
events for both the OTFC and spray formulations were nausea,
vomiting, constipation, diarrhoea, dizziness, asthenia, urinary
tract infection and pyrexia, with very similar results for both
formulations.59
Orally disintegrating sublingual tablet
One phase III study compared the sublingual formulation with
placebo.61 Patients were titrated in an open-label setting, fol-
lowed by a double-blind, efﬁcacy phase, lasting 2 weeks, in
which the titrated dose was compared with placebo in a cross-
over study, followed by a 12-month safety study, using open-
label sublingual fentanyl. An overview of the adverse events
with the sublingual formulation is provided in table 9. The most
frequent side effects were nausea, vomiting, headache and som-
nolence. During the study period, 31% of patients experienced
side effects that were considered to be possibly or probably
treatment related. Eighteen per cent of patients experienced
severe adverse events, but only 1% was considered to be treat-
ment related.61
One non-comparative phase IV study enrolled 217 patients
with breakthrough cancer pain for an observation period of
28 days. Thirty-three patients (15%) experienced at least one
adverse event during the observation period. Twelve patients
(5.5%) experienced adverse events that were considered to be
treatment related. The most frequent events were nausea,
fatigue, dizziness and vomiting.80 Another non-comparative
phase study investigated safety during up to 12 months. Of 139
patients who received at least one dose of the study medication,
84% experienced at least one adverse event, with the most
common adverse events being nausea (23%), fatigue (15%) and
vomiting (13%). Thirty-ﬁve per cent of the adverse events
reported were thought to be possibly or probably related to the
study medication. Of the 33% of serious adverse events
reported, none were considered to be related to the study medi-
cation. The incidence of withdrawal due to adverse events
was 27%.81
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Table 9 Adverse drug events in randomised controlled studies
Formulations
AE
total (%)
AE
drugs (%) AE withdrawal (%) Nausea (%) Vomiting (%) Constipation (%) Fatigue/somnolence (%) Dizziness (%) Drowsiness (%) Reference
OTFC
Nasal spray
35
46
7
8
8
8
3
5
3
4
3
2
2
3
59
FPNS
Nasal spray
60
SLF
Placebo
73 31 23 12 5 5 61
SLF
Placebo
26 3 7 7 7 10 62
SLF
IRMS oral
25 0 0 15 5 15 10 63
SLF-E
Placebo
4 6 64
OTFC
IRMS oral
13 13 10 15 7 7 65
OTFC
Mor IV
8
4
19
13
66
OTFC
Placebo
14 3 5 8 17 67
Buccal
Placebo
8 22 11 8 12 22 68
Buccal
Placebo
66 13 6 6 8 11 69
Buccal
Placebo
83 11 14 27 70
Buccal film
Placebo
50 5
(drug related)
4 2 6 5 71
Nasal spray
Placebo
20 5 5 72
FPNS
IRMS oral
33 (400 mg dose)
16
3
1
5
4
5
2
5
1
3
0^
73
FPNS
Placebo
51 9 11 4 8 75
AE, adverse event; FPNS, fentanyl pectin nasal spray; IRMS, immediate release morphine sulfate; IV, intravenous; Mor, morphine; Nasal, fentanyl nasal spray; OTFC oral transmucosal fentanyl citrate; SLF, sublingual fentanyl (Abstral); SLF-E, sublingual
fentanyl ethypharm (Recivit).
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Sublingual tablet
In one study 77 treatment-emergent adverse events (TEAEs)
were reported. However, only 40 (52%) of these were consid-
ered to be directly related to the study treatment. Most were
noted to be of mild to moderate severity. The most common
TEAEs were typical of opioid administration and included
vomiting (5.5%), nausea (4.4%), diarrhoea (3.3%), dry mouth
(3.3%) and somnolence (2.2%).64
OTFC
An overview of the adverse events with OTFC in clinical studies
is provided in table 9. The most common adverse events were
dizziness, nausea, vomiting, constipation and somnolence.65–67
Only the comparative study between OTFC and IV morphine
provided speciﬁcations of adverse events in each treatment arm;
however, it found that adverse events owing to the treatment
were indistinguishable from those resulting from the back-
ground opioid analgesia.66 One study compared two titration
regimens of OTFC, starting with either 200 mg or 400 mg
doses. The side effects seen in this study were considered to be
‘possibly’, ‘probably’ or ‘almost certainly’ related to the study
medication and included somnolence (28%), dizziness (14%),
nausea (10%) and headache (5%). After dose titration and on
stabilisation of the dose the incidence of such adverse events
reduced by approximately half.82
Long-term safety of OTFC was investigated in two studies. A
total number of over 38 000 episodes of BTP was included in
one study. The mean duration of treatment was 91 days (range
1–423 days). Adverse events that were considered to be related
to the study medication included somnolence (9%), constipation
(8%), nausea (8%), dizziness (8%) and vomiting (5%). Four per
cent of patients withdrew owing to side effects.83 Another study
investigated OTFC for up to 6 months. In the initial phase,
nausea (reported by 14% of patients) was the most frequent
side effect, followed by stomatitis, vomiting and dizziness (7%
each). Ten per cent of patients withdrew owing to side effects.
Similar adverse effects were noted in the long-term study up to
6 months but the number of reports was very low.84
Buccal tablet
Two placebo controlled studies made no distinction between
active or placebo-treated episodes concerning adverse events.
The incidence of adverse events is shown in table 9. Headache
was observed in both studies: 15% and 6%, respectively. Local
reactions at the application site were seen in 2% and 10% of
patients.68 69
One study provided information on the tolerability of the
buccal tablet in a relative large population of 232 patients. The
most frequent adverse events were nausea: 37%, vomiting:
22%, dizziness: 20%, fatigue: 16%, constipation: 14%,
anaemia: 14%, headache: 14%, somnolence: 13%, peripheral
oedema: 13%, abdominal pain: 11%, dehydration: 11%, anor-
exia, depression and diarrhoea: 10% each. Treatment was dis-
continued by 33% of study participants owing to adverse
events; however, only 31% of these withdrawals were related to
the study medication. The remaining 69% of withdrawals were
attributed to adverse effects associated with the patients under-
lying disease. Most of the withdrawals occurred during the
maintenance phase rather than the titration phase.87
One pharmacokinetic study, performed in healthy opioid
naïve participants also provided information on tolerability of
the buccal tablet at dosages of 600–1300 mg. Each dose was
used in about 100 patients. There was no clear relationship
between dose and adverse events, although trends did show that
overall fewer adverse events were reported with the 600 and
1000 mg dosages (30% and 27% of patients receiving each
dose, respectively) than with 1200 and 1300 mg doses (43%
and 37%, respectively). No statistics were provided. Dizziness
was reported more frequently at the higher dosages (7–11%)
than with the 600 mg dose (1%).41 The relevance of this study
is limited because it was performed in healthy subjects.
One study investigated the long-term (18 months) safety of
the buccal tablet in non-cancer pain. During maintenance treat-
ment in a large cohort (n=646), 11% of patients withdrew
because of adverse events. Other reasons for discontinuation
were withdrawal of consent (11%) and non-compliance (9%).
The observed adverse events were typical of opioids: nausea
(17%), back pain (15%), vomiting (12%), headache (11%) and
constipation (9%).93
Buccal ﬁlm
In one study TEAEs led to discontinuation of treatment in 14%
of study participants. The most common adverse events leading
to discontinuation were nausea and vomiting. Drug-related
adverse events were seen in 25% of patients.71
Nasal spray
One placebo controlled study did not distinguish between active
or placebo-treated episodes for adverse events. The incidence of
adverse events is shown in table 9. At least one treatment
related adverse event was noted in 4.6% of study participants.
Most other adverse events were considered unrelated to drug
treatment. Those adverse events resulting from the study treat-
ment were nausea, vomiting and constipation.72
FPNS
One study compared FPNS with IRMS. The incidence of
adverse events is shown in table 9. The pattern of adverse
events was similar in both groups, but the overall incidence of
adverse events was higher in the FPNS group. A greater number
of treatment-related adverse events were seen with the higher
doses of FPNS than with lower doses. Most common adverse
events reported were somnolence, vomiting, dehydration and
nausea, and the most serious adverse events were not considered
to be related to the study drug. No statistical information was
provided in the article.73
One study compared FPNS with placebo, and included the
incidence of adverse events in the placebo arm of the study.75
Adverse events were seen in 51% of patients with the nasal
spray versus and in only 5% with placebo. Most adverse events
were of mild or moderate severity, and increasing the dosage
did not increase either the frequency or severity. The incidence
of adverse events is shown in table 9.
Table 10 Score for ease of administration
Formulation Trade name Score (%)
Sublingual Abstral 100
Sublingual Recivit 75
Oromucosal Actiq 60
Buccal tablet Effentora 85
Buccal film Breakyl 85
Nasal spray Instanyl 100
Nasal spray PecFent 100
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The pectin nasal spray was well tolerated in a German study
in a population of 225 subjects with BTP in cancer.94
A further study investigated the medium-term (16 weeks)
safety of the FPNS. During maintenance treatment in a large
cohort (n=356, of whom 110 completed the 16 week period),
adverse events were seen in 25% of patients. These were
reported as mild to moderate in severity, and most commonly
included dizziness (5.2%), vomiting (3.7%), constipation and
somnolence (both 3.5%). The number of patients reporting one
adverse event was higher after administration of an 800 μg dose
(20.1%) than with lower doses (11.2%, 9.5% and 13.4% with
100, 200 and 400 mg doses, respectively).89
The number of comparative studies is disappointingly limited,
which makes it difﬁcult to judge the relative safety and tolerabil-
ity of different fentanyl formulations. Only one open-label ran-
domised study was performed: between OTFC and the nasal
spray. In this study, sponsored by the manufacturer of the nasal
spray, no difference in the incidence of side effects was seen.59
The other formulations have only been compared with placebo
and not with each other, but the adverse events seem to be
similar for all formulations.
All formulations are awarded 60%.
DOSAGE FREQUENCY/EASE OF ADMINISTRATION
All formulations may be administered up to four times daily. If
more frequent administration is necessary, adjustment of main-
tenance dosages or selection of opioids is necessary. There are
no differences between the fentanyl formulations in this respect.
The number of dosages per breakthrough event is one or two
for each formulation. Again, there are no differences between
the formulations in this respect. This is, however, the case in a
limited number of patients and was scored under Formulations.
One study compared the OTFC formulation and the nasal spray
in patients with breakthrough cancer pain and considered ease
of use and patient preference as part of its outcomes. A marked
difference was seen in patient preference, with over 60% of
patients considering the nasal formulation very easy to use,
compared with 11% for the OTFC formulation. A description
of very easy or easy to use was given by 90% of patients for the
nasal spray and 40% for the OTFC formulation.59 It must be
remembered that the study was sponsored by the manufacturer
of the nasal spray. Patient information and counselling are key
factors in a patient’s opinion of the ease of use, and these proce-
dures were not described in any detail in this study. The results
of this study need to be conﬁrmed in other, independent,
studies before conclusions can be drawn.
Differences in the application of OTFC may, however, affect
its efﬁcacy. The absorption may be reduced in patients with a
dry mouth and it may be troublesome to apply the product for
15 min or longer. Shorter application may affect efﬁcacy and
safety as more of the product may be swallowed rather than
absorbed via oral mucosa.
The nasal spray should be used in an upright position, which
usually means no major problem for bedridden patients. In
cases of rhinitis, the nose should be emptied immediate before
the spray is used.
No studies have described the acceptance of buccal tablets.
However, two of the authors who prescribed buccal tablets
reported that a signiﬁcant proportion of patients experience an
unpleasant taste and problems with having the tablet in the
mouth for å longer period. Although not documented in any
studies, this is taken into account when scores were considered.
The buccal formulations score is 15% lower.
We found one relevant study that studied the practical aspects
of the various formulations of fentanyl in BTP. The study was
not sponsored by any company. The investigators studied
placebo formulations (supplied by the manufacturers) of an
orally disintegrating sublingual tablet, a buccal tablet and a nasal
spray and these were compared with the medication that the 30
patients with cancer were using (oral solution or tablets of mor-
phine21 or oxycodone.7 One patient was receiving subcutaneous
morphine). The formulations were judged on accessibility (ease
with which a dose could be obtained from its container), admin-
istration, palatability (based on taste and other sensations),
overall satisfaction (efﬁcacy and tolerability; studies for the usual
medication only, because the other formulations were supplied
as placebo) and overall impression.95 For accessibility, no differ-
ences were seen between the disintegrating sublingual and
buccal tablet, but both formulations were judged signiﬁcantly
better than the nasal spray. For ease of administration, the disin-
tegrating sublingual tablet performed signiﬁcantly better than
the buccal tablet (p=0.04), but the difference with the nasal
spray was just statistically signiﬁcant (p=0.05). In particular, the
quicker dissolution of the sublingual tablet was considered
advantageous. The sublingual tablet also performed better than
the other formulations for palatability (p<0.01). It should be
noted that placebo formulations were used and therefore the
results are not by deﬁnition also valid for the fentanyl formula-
tions. This resulted in a better overall acceptability for the sub-
lingual placebo tablet than for the buccal tablet (p<0.01) and
nasal spray (p=0.04),95 which complies well with the results
from the SOJA score.
One of the authors commented that opening of the original
package of FPNS is difﬁcult for many patients and that the sub-
lingual formulations are very small and difﬁcult to handle for
patients with arthritic or shaking hands.
The sublingual tablet (Recivit) must be kept under the tongue
for 30 min. The fentanyl in the sublingual tablet is not incorpo-
rated throughout the tablet, but in the outer layer, allowing
rapid dissolution of fentanyl, whereas the neutral core dissolves
more slowly.96 Although this formulation has been very recently
introduced and no patient data are available, the same argument
is valid as for the buccal tablet; this formulation scores 25%
lower. Scoring of the formulations is shown in table 10.
DOCUMENTATION
The score for this criterion was divided over four subcriteria.
The ﬁrst two subcriteria are indicative of the overall clinical
documentation of the drugs in randomised controlled clinical
studies. A large number of clinical studies and a large number of
patients included in these studies provide conﬁdence in the clin-
ical efﬁcacy and safety of this drug in the studied population.
The third and fourth criteria are indicative of the overall clinical
experience with the drug. These subcriteria may introduce a
bias to the advantage of older drugs. The safety of a newly
introduced drug cannot be guaranteed since there are a limited
number of clinical studies and relatively small number of
patients. Patients most at risk of adverse events (eg, those with
renal impairment) are usually excluded from trials. Both the
number of patients who have been treated worldwide and the
period that a certain drug has been available are important, as it
may take time until adverse reactions occur.
1. Number of comparative studies
The number of randomised comparative clinical studies with
rapid-acting fentanyl formulations is an important determinant
of the clinical documentation.
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Five per cent of the relative weight for this subcriterion was
awarded for each double-blind comparative study. A formulation
is awarded 100% when 20 studies are available.
2. Number of patients in these studies
Besides the number of clinical studies, the number of patients
who have been treated with the drug in question must also be
taken into consideration.
One per cent of the relative weight for this subcriterion was
awarded for every 10 patients enrolled in double-blind com-
parative studies. A formulation is awarded 100% when over
1000 patients are included.
3. Number of years marketed
The number of years that a product has been marketed in any
country in the world provides information on the clinical
experience with the drug. If a product is on the market for
more than 10 years it is very unlikely that serious adverse reac-
tions will be observed that have not been seen in the ﬁrst
10 years after its introduction.
Ten per cent of the relative weight for this subcriterion was
awarded for every year that the product has been available on
the market.
4. Number of patient-days worldwide
Besides the number of years that a product is on the market,
the number of patient-days experience with the drug also plays
a role.
One per cent of the relative weight for this subcriterion was
awarded for every million patient days worldwide.
The results for the different formulations are summarised in
table 11.
Results
The number of evaluable patients in the study by Thronæs
et al78 (23 patients) was too low to include this study in the
documentation assessment.
There is extensive clinical experience with the molecule fen-
tanyl. It is highly unlikely that new serious adverse events will
be reported using the formulations included in this analysis.
Therefore, all formulations were assigned the full score for
years on the market and patient-days experience.
SOJA score
The SOJA score is presented in table 12.
DISCUSSION
The evaluation of the criteria by the SOJA method is highly
standardised in order to promote unbiased judgement of drugs
from various pharmacological categories based on clinically rele-
vant criteria. Of course, there is debate about the correct
scoring system for each criterion and individual decisions are
highly subjective. This is the case with any method used to
quantify the properties of drugs. The SOJA method is intended
as a tool for rational drug decision-making, enabling clinicians
and pharmacists to include all relevant aspects of a certain
group of drugs, thereby preventing formulary decisions being
based on only one or two criteria. Additionally, possible ‘hidden
criteria’ (such as personal ﬁnancial interest) are excluded from
the decision-making process. The outcome of this study should
be seen as the basis for discussions within formulary committees
and not as the absolute truth.
Acquisition cost was not included as a selection criterion to
make the score internationally applicable. The present matrix
can be used as a preselection tool of the most suitable formula-
tions from a quality point of view. Because prices may
differ between institutions and different healthcare systems,
individual procurement procedures should lead to a selection of
the best formulations.
There is some overlap between the applied selection criteria.
The number of available formulations is related to dosage
Table 11 Documentation of the different formulations
Formulation Trade name Number of studies Number of patients Number of years on the market Patient-days experience Reference Score (%)
Sublingual Abstral 3 123 >10 >100 61–63 57
Sublingual Recivit 1 76 >10 >100 64 53
Oromucosal Actiq 4 296 >10 >100 59, 65–67 62
Buccal tablet Effentora 3 237 >10 >100 68–70 60
Buccal film Breakyl 1 82 >10 >100 71 53
Nasal spray Instanyl 3 235 >10 >100 59, 60, 72 60
Nasal spray PecFent 4 283 >10 >100 60, 73–75 62
Table 12 Score and ranking
Strengths Bioavailability Interactions Efficacy Side effects Ease of use Documentation Total
RWF 60 50 50 350 150 140 200 1000
Formulation Trade name
Sublingual Abstral 60 34 40 245 90 140 114 723
Sublingual Recivit 54 33 40 245 90 105 106 673
Oromucosal Actiq 48 26 40 245 90 84 125 658
Buccal tablet Effentora 54 30 40 245 90 119 120 698
Buccal film Breakyl 48 34 40 210 90 119 106 647
Nasal spray Instanyl 42 33 40 245 90 140 120 710
Nasal spray PecFent 36 30 40 245 90 140 124 705
RWF, rating weight factor.
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frequency. If fewer formulations are available, it may be neces-
sary to apply two dosages instead of one. On the other hand, a
large number of strengths allow minor dose increases instead of
doubling the dose, because few strengths are available. This may
also reduce cost (or maybe side effects) during the titration
period. This was taken into account in the criterion available
formulations and not in acquisition cost.
The onset of action is a relevant selection criterion. We have,
however, not included this in the set of criteria, because there
were insufﬁcient direct comparative data to make a good estima-
tion of the rate of action of the various formulations of fen-
tanyl. For this reason we chose variability in the rate of
absorption as a pharmacokinetic criterion.
There is limited evidence that the fentanyl formulations act
more quickly than immediate release morphine or oxycodone.
Their pharmacokinetics are obviously more favourable, but only
three studies have compared a fentanyl formulation with imme-
diate release morphine. One study compared OTFC with oral
morphine and a (slightly, but signiﬁcantly) better clinical efﬁcacy
was found for OTFC at all time points between 15 and
60 min.65 Another study compared FPNS with morphine. The
nasal spray performed better than morphine at 15 min or later,
but the absolute differences were limited (0.2–0.5 points differ-
ence in PID).73 In both studies all patients entered a titration
phase with fentanyl before the start of the study. Only patients
showing successful titration with fentanyl entered the study,
which might have led to a selection bias compared with mor-
phine. The sublingual tablet was more effective than morphine
immediate release in a small-scale study.63 In that study, mor-
phine was used in the titration phase of the patients randomised
to morphine. OTFC was, however, less effective as IV mor-
phine.66 A meta-analysis concluded that fentanyl formulations
showed better clinical efﬁcacy than placebo, while no superior-
ity versus placebo could be demonstrated for morphine.97
Cancer BTP is a heterogeneous syndrome which deserves
thorough analysis by the physician. It requires continuous
patient education and support on how to deal with various
types and characteristics of BTP using both pharmacological and
non-pharmacological treatments. Many of the studies referenced
in this manuscript do not specify the type and characteristics of
BTP in detail and correlations between BTP and response or
non-response to the drugs are not investigated. In addition
several of these studies have different outcomes.
The intensity of breakthrough episodes may alter with time,
which complicates optimal treatment. The recently published
European Society of Medical Oncology guideline for BTP in
cancer states that rapidly acting fentanyl formulations have
many advantages which suit the proﬁle of unpredictable BTP in
cancer. Immediate release oral opioids can be used in predict-
able BTP, such as washing or changing clothes.93 It should be
kept in mind that the huge diversity of BTP affects the choice of
the ‘optimal medicine’.
The acquisition cost of all fentanyl formulations included in
this analysis is relative large, especially compared with immedi-
ate release morphine or oxycodone, which are often used in the
treatment of BTP. This should be taken into consideration
before selecting a fentanyl formulation. The large difference in
cost was the main reason why the UK National Institute of
Health and Care Excellence (NICE) recommended immediate
release morphine as ﬁrst choice for the treatment of BTP rather
than rapid acting fentanyl products.8
Some interesting differences in score between the formula-
tions are seen. Of course, the scoring presented here is based on
the weights assigned by the authors. The essence of the SOJA
method is that users of the method may assign their own relative
weight to each selection criterion. This interactive programme is
available on the internet at tablet.sojaonline.nl. Other relative
weights will of course affect the relative scores for the formula-
tions. With scarcely any comparative studies available, it is not
possible to reliably evaluate the formulations on the most
important selection criteria, clinical efﬁcacy and safety.
With these limitations in mind, the sublingual formulations
show higher scores than the other formulations. Because no
independent studies were performed concerning patient prefer-
ence for all the available formulations, there is a clear need to
involve patients in the selection process of immediate acting fen-
tanyl formulations. Patient education about the heterogeneity of
BTP is essential. The preference of the patient for the various
available formulations is highly relevant, also taking into consid-
eration the speciﬁc situation of the patient (common cold and
nasal spray as well as dry mouth or stomatitis for the buccal and
sublingual formulations). No independent studies have investi-
gated patient preference for any of the formulations and patients
need to be well informed about their pros and cons. Because
there are no known differences in clinical efﬁcacy or safety,
patient preference should be a very important selection criter-
ion. The OTFC formulation seems less patient-friendly than
other formulations, but this needs veriﬁcation in more compara-
tive (and independent) studies. It is doubtful whether such
studies will ever be performed.
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